Report of Anesthesia in a Previously

KNOWN (or suspected) MALIGNANT HYPERTHERMIA SUSCEPTIBLE PATIENT

("MHS Report")

INSTRUCTIONS:

This form is to be filled out by an anesthesiologist or other health care provider.

- 1. Complete this form each time you anesthetize a patient who has been **previously diagnosed** (or suspected) as malignant hyperthermia (MH) susceptible. (Use the MHN form if a MH muscle biopsy was negative.) This form may also be used to register a nonanesthetic related event such as heat or exercise related cardiovascular collapse or rhabdomyolysis in a patient who has been **previously diagnosed** (or suspected) as malignant hyperthermia (MH) susceptible.
- 2. Please fill out as soon as patient is stable, preferably within 48 hours of the event.
- 3. The attending anesthesiologist, or other physician, should review the completed form.
- 4. If the patient has been registered previously in the NAMH Registry, please ask the patient for his/her Registry identification number and record it in the space provided.
- A copy of this report may be given to the patient.
 Return the original completed form to:
 The North American Malignant Hyperthermia Registry

University of Florida
Department of Anesthesiology
1600 SW Archer Road, PO Box 100254
Gainesville, FL 32610

North American MH Registr	v Number	(for	office	use)
---------------------------	----------	------	--------	------

MHS REPORT
Version 8.6 May 2014

		Comment	
) .			
c.		Comment	
Pati	ient's Initials		
	first middle last		
	s consent been obtained to enter	r patient's name into the Reg	gistry?
che	ck one		
	() yes		
	() no		
	() no		
If y	() no es, please complete a-g on follo	owing page.	
•	es, please complete a-g on follo		
•			EEN OBTAINED
•	es, please complete a-g on follo		EEN OBTAINED
Not	es, please complete a-g on follo		EEN OBTAINED
Not	es, please complete a-g on follo		EEN OBTAINED middle
Not	es, please complete a-g on follote: DO NOT COMPLETE IF Patient's name	CONSENT HAS NOT B	
Not	es, please complete a-g on follote: DO NOT COMPLETE IF Patient's name	CONSENT HAS NOT B	
Not	es, please complete a-g on follote: DO NOT COMPLETE IF Patient's name last Patient's previous name	first	middle
Not	es, please complete a-g on follote: DO NOT COMPLETE IF Patient's name	CONSENT HAS NOT B	

d.	Patient's Address
	street address
	city state/province zip/postal code
	country
e.	Phone number (Home) () (Work) ()
f.	Patient e-mail address
g.	Date of patient's birth
year	month day
<u>OGRAI</u>	PHIC INFORMATION
	eck one) male () female
Weigh	t kilograms OR lbs
Height	cms
Year o	of patient's birth
	e. f. g. OGRAI Sex cho (Weight Height

check as many as apply	
(data utilized for demographic purpose	• •
() Caucasian	() African
() Hispanic	() East Asian
() African-American	() South Asian
() Native American	() Middle Eastern
() Hawaiian or Pacific Islander	
() other (specify):	
Body Build	
check one	
() Normal	() Lean
() Muscular	() Obese
() Postpartum	
State or province of the patient's residue. State or province of the location in w	idence which anesthesia was given or the non-anesthetic
State or province of the patient's resi	idence
State or province of the patient's residue. State or province of the location in we event occurred. Reporting physician's name (optional)	which anesthesia was given or the non-anesthetic
State or province of the patient's residue. State or province of the location in we event occurred. Reporting physician's name (optional)	idence which anesthesia was given or the non-anesthetic
State or province of the patient's residue. State or province of the location in we event occurred. Reporting physician's name (optional physician's name)	which anesthesia was given or the non-anesthetic
State or province of the patient's residue. State or province of the location in we event occurred. Reporting physician's name (optional physician's name) Facility type:	which anesthesia was given or the non-anesthetic
State or province of the patient's residue. State or province of the location in we event occurred. Reporting physician's name (optional physician's name) Facility type: () Hospital	which anesthesia was given or the non-anesthetic al)
State or province of the patient's residue. State or province of the location in we event occurred. Reporting physician's name (optional physician's name) Facility type: () Hospital () Ambulatory Surgical facility loc	which anesthesia was given or the non-anesthetic
State or province of the patient's residue. State or province of the location in we event occurred. Reporting physician's name (optional physician's name) Facility type: () Hospital () Ambulatory Surgical facility local physician ambulatory surgical physician ambulatory surgical facility local physician ambulatory surgical physi	which anesthesia was given or the non-anesthetic al)

ANESTHETIC HISTORY

15.	Patient's anesthetic history is positive for:
	check all applicable
	() clear-cut clinical MH episode(s)
	() possible MH (not clear-cut MH)
	() masseter muscle rigidity only
	() positive caffeine halothane contracture test
	() positive genetic findings (specify)
	() positive calcium uptake test (performed in Boston)
	() other (<i>specify</i>)
	() none of the above
	() unknown
16.	How many times was this patient anesthetized prior to this evaluation?
17.	How many were general anesthetics?
	- () unknown but > 0 () unknown
18.	Indicate the number of anesthetics with the following agents:
	volatile agents without succinylcholine
	volatile agents with succinylcholine
	succinylcholine without other known triggering agents
	() unknown

FAMILY HISTORY

19.	Family history is positive for:
	check all applicable
	() malignant hyperthermia
	() confirmed by CHCT
	() confirmed by genetic test (specify result)
	() masseter spasm
	() intraoperative death <u>not</u> thought to be MH
	() sudden infant death syndrome or cot death
	() sudden death from unknown cause at < 45 year >1.5 years
	() heatstroke
	() neurolept malignant syndrome
	() intolerance to heat
	() chronic muscle pain
	() frequent muscle cramps
	() chronic muscle weakness
	() exercise intolerance due to muscle pain, weakness or fever
	() episodes of dark urine and muscle pain
	() myopathies
	specify type; write unknown if not known:
	() idiopathic creatine kinase elevation
	() diabetes
	() Type 1
	() Type 2
	() none of the above
	() unknown
<u>MED</u>	OICAL HISTORY
20.	Has the patient had any of the following?
	check all applicable
	() muscle weakness interferes with daily activity at least once/week
	() muscle cramps interfere with daily activity at least once/week
	() cola colored urine
	() heat stroke or heat prostration
	. ,
	() oral (or rectal/axillary equivalent) fever>38.6□C or 101.4□F at least 6 times/year without medical cause
	() recent generalized infection
	If there was infection, how long ago was it? (days)
	() recent use of cholesterol lowering drugs
	If so, which drug, and when was it last ingested? (days)
	() a regular regimen of physical activity?
	If so, when was the last work-out? (days)
	() ingestion of any medicine to improve muscular performance
	() intolerance to heat

	() exercise intolerance due to muscle pain, weakness or fever
	() diabetes
		() Type 1
		() Type 2
	() none of the above
	() unknown
21.	Has p	patient ever had physical findings of:
	check	k all applicable
	() increased muscle tone
	() decreased muscle tone
	() generalized muscle weakness
	() myopathy specify type; write unknown if not known:
	() ptosis
	() strabismus
	() hiatal hernia
	() inguinal hernia
	() umbilical hernia
	() undescended testes
	() clubbed foot
	() joint hypermobility
	() kyphoscoliosis (moderate or severe; curve >45°)
	() pectus carinatum
	() winged scapulae
	() skeletal fractures (more than 2)
	() gallstones
	() kidney stones
	() laryngeal papillomas
	() other (specify):
	() none of the above
	() unknown
MAN	<u>IAGEN</u>	IENT for this event.
22	Vacan	of arrant
22.	i ear	of event
23.	If thi	s event is an anesthetic, continue If not skip to 40
		· · · · · · · · · · · · · · · · · · ·
check	• •	<u> </u>
) cardiothoracic
	() dental
	() ear, nose, or throat
	() eye
	() general surgery
	Type k all app (((of procedure scheduled olicable) cardiothoracic) dental) ear, nose, or throat) eye

	() laparoscopic surgery
	() abdominal
	() pelvic
	() other (specify)
	() gynecology
	() neurosurgery
	() thoracoscopic surgery (thoracic)
	() obstetrics
	() oral surgery
	() orthopedic
	() plastic surgery
	() radiology
	() urology
	() vascular
	() transplant
	() other (specify):
24.	Was the procedure an emergency?
	check one
	() no () yes
25.	Anesthetic preparation included:
	check all applicable
	() dedicated vapor-free anesthesia machine
	() anesthesia workstation flushed with either oxygen or air
	() activated charcoal filter on the inspiratory limb
	() autoclaving ventilator diaphragm and integrated breathing system
	() free-standing ventilator NOT part of anesthesia workstation
	() anesthetic vaporizers bypassed
	() anesthetic vaporizers drained
	() new carbon dioxide absorbent
	() new anesthesia circuit
	() new mask
	() new endotracheal tube
	() other (specify):
	() unknown
26a.	How many minutes was the anesthesia machine flushed?
	Do not complete if not applicable
	minutes
26b.	What flow rate was the anesthesia machine flushed at:
•	Do not complete if not applicable
	L/minute

What type of anesthesia workstation was used? Type Model
Was a premedication other than dantrolene (Dantrium) given? check one () no
() yes
Was dantrolene given before anesthetic induction? check one
() no
() yes
If no, skip to question 31
Pre-induction dantrolene administration:
dose (mg)
Number of doses
: Time final dose begun (military time)
: Time final dose completed (military time)
Route of initial dantrolene administration:
check all applicable
() iv
() po
Were any complications from dantrolene administration noted? <i>check one</i>
() no
() yes
If no, skip to question 31
What dantrolene associated complications were observed?
check all applicable
() phlebitis
() excessive secretions
() gastrointestinal upset
() hyperkalemia
() muscle weakness
() respiratory failure
() other (<i>specify</i>):

	check all monitoring used	
	() blood pressure monitor () end-tidal PCO ₂	
	() electrocardiograph () pulse oximeter	
	() stethoscope () bladder (Foley) catheter	
	() arterial catheter	
	() central venous catheter	
	() pulmonary artery catheter	
	() pullionary artery catheter	
	temperature probes:	
	() axillary	
	() bladder	
	() esophageal	
	() nasopharyngeal	
	() rectal	
	() skin-electronic	
	() skin-liquid crystal	
	() tympanic	
	()other (specify):	
34.	Were local anesthetic agents used? check one () no () yes	
35.	Route of local anesthetic administration:	
	check all applicable	
	() epidural	
	() intercostals	
	() intravenous	
	() major plexus block	
	() spinal	
	() subcutaneous	
	() topical or mucosal	
	() other (specify):	
36.	Local anesthetic drugs and vasoconstrictors utilized:	
	check all applicable	
	• •	
	() benzocaine (Americaine)	
	() benzocaine (Americaine)() bupivacaine (Marcaine)	
	() benzocaine (Americaine)() bupivacaine (Marcaine)() levo-bupivacaine	

	() cocaine	
	() etidocaine (Duranest)	
	() lidocaine (Xylocaine)	
	() mepivacaine (Carbocaine)	
	() prilocaine (Citanest)	
	() procaine (Novocain)	
	() ropivacaine (Naropin)	
	() tetracaine (Pontocaine)	
	() ephedrine	
	() epinephrine	
	() neosynephrine	
37.	Other anesthetic agents utilized (including	premedication):
	check all applicable	
	() atropine	() no potent volatile anesthetic
	() glycopyrrolate (Robinul)	
	() scopolamine (Hyoscine)	() fentanyl and droperidol
		(Innovar)
	() droperidol (Inapsine)	() meperidine (Demerol)
	() hydroxyzine (Vistaril)	() morphine
	() promethazine (Phenergan)	() opium (Pantopon)
	() diphenhydramine (Benedryl)	() sufentanil (Sufenta)
		() hydromorphone (Dilaudid)
	() ketorolac (Toradol)	
	() acetaminophen (Tylenol)	() nalbuphine (Nubain)
		() naloxone (Narcan)
	() diazepam (Valium)	
	() lorazepam (Ativan)	() atracurium (Tracrium)
	() midazolam (Versed)	() gallamine
	() nitrous oxide	() pancuronium (Pavulon)
		() rocuronium (Zemuron)
	() etomidate (Amidate)	() vecuronium (Norcuron)
	() ketamine (Ketalar)	() NO succinylcholine
	() propofol (Diprivan)	
	() alfentanil (Alfenta)	() edrophonium (Tensilon)
	() fentanyl (Sublimaze)	() neostigmine (Prostigmin)
		() physostigmine (Antilirium)
	() other (<i>specify</i>):	

38.	Type of anesthetic
	check all applicable
	() monitored anesthesia care
	() regional anesthesia
	() spinal anesthesia
	() epidural anesthesia
	() general anesthesia without laryngeal mask airway or endotracheal intubation
	() general anesthesia with a laryngeal mask airway
	() general anesthesia with endotracheal intubation
39.	Type of ventilation
	check one
	() spontaneous
	() assisted
	() controlled
40.	Time of anesthetic induction for general/regional anesthetic?
	(hours and minutes since induction)
41.	Earliest time the patient was stable in recovery room or intensive care unit? (after induction)
	(hours and minutes since induction)
<u>MH (</u>	COMPLICATIONS
42.	Were any signs of MH noted?
	check one
	() no () yes
If no,	skip to comments

43.	Abnormal signs noted (signs felt to be inappropriate in the judgment of the attending
	anesthesiologist or other physician)
	NUMBER in order of appearance
	(a number may be used more than once if signs noted simultaneously)
	masseter spasm
	generalized muscular rigidity
	cola colored urine
	tachypnea
	hypercarbia
	cyanosis
	sinus tachycardia
	ventricular tachycardia
	ventricular fibrillation
	elevated temperature
	rapidly increasing temperature
	sweating
	excessive bleeding
	hypertension > 20% of baseline
	other (specify):
44.	Signs
fill in	the blanks
o .	time first adverse sign noted (after induction)
	(hours and minutes since induction)
time second adverse sign noted (after induction)	
	(hours and minutes since induction)
	maximum temperature noted (°C) OR
	maximum temperature noted (° F)
	time maximum temperature noted (after induction)
	(hours and minutes since induction)
	maximum end-tidal pCO ₂ noted (mmHg)
	time maximum end-tidal CO ₂ noted (after induction)
	(hours and minutes since induction)

45. Laboratory Evaluation

fill in the blank, write unknown if results not known

most abnorma	al arterial blood gas after MF FiO2	I was suspected		
•	pH			
	PCO2 (mmHg)	liters/minute		
	PO2 (mmHg)	ventilation at time		
·_	BE (mEq/L) (specify ±) Bicarbonate (mEq/L)	blood gas was obtained		
	Time (after induction) (hours and minutes since in	nduction)		
peak lactic ac				
mmol/I	L			
peak K+				
mE	q/L or mmol/L			
	creatine kinase*	*recommended intervals for creatine		
, U/L		kinase determination are 0, 6, 12, 24		
nours a	after induction	hours after MH reaction suspected		
peak serum myoglobin				
	ng/ml			
hours	after induction			
peak urine myoglobin				
,	mg/L			
hours	after induction			

	PT (prothrombin time) seconds	INR —·—	PTT (partial thromboplastin time) seconds
	laboratory upper limit of normal seconds		laboratory upper limit of normal seconds
	platelet count		fibrinogen mg/dl
46. chec	Treatment given for signs <i>k all treatments utilized; fill</i>		
	() Hyperventilation v	with 100% oxyge	en
	() Intraoperative or p	ostoperative dan	trolene given
		ne required (after	
	· ·	ours and minutes	,
		al dose given afte	er induction (mg)
	() Active cooling Mathod (specify)	\	
	() Fluid loading)	
	ml/kg		
	_	fv)	
	() Furosemide	<i>J</i> /	
	() Mannitol		
	() Bicarbonate		
	() Glucose, insulin		
	() Bretylium		
	() Lidocaine		
	() Procainamide		
	() Defibrillation		
	() CPR() Other (specify):		
	() Other (specify)		
47.	Did the patient survive the <i>check one</i>	e initial MH react	ion?
	() no		
	() yes If no, pleas	e skip to question	n 51

48.	Did the patient develop additional signs or symptoms after initial adequate treatment (recrudesce)? <i>check one</i> () no		
	() yes If no, please skip to comments		
49.	When did the patient recrudesce? hours after induction		
	nours after induction		
50.	Did the patient survive the recrudescence?		
	check one		
	() no		
	() yes		
51.	If the patient died, what was the cause of death?		
	check one		
	() MH		
	() other (<i>specify</i>):		
CON Optic	IMENTS ON PATIENT onal		